234 results on '"Palermo, Pietro"'
Search Results
2. Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways
3. Influence of exertional oscillatory breathing and its temporal behavior in patients with heart failure and reduced ejection fraction
4. The importance of re-evaluating the risk score in heart failure patients: An analysis from the Metabolic Exercise Cardiac Kidney Indexes (MECKI) score database
5. Pick Your Threshold: A Comparison Among Different Methods of Anaerobic Threshold Evaluation in Heart Failure Prognostic Assessment
6. Activities of daily living in heart failure patients and healthy subjects: when the cardiopulmonary assessment goes beyond traditional exercise test protocols
7. “Under the Bridge”: Looking for Ischemia in a Patient with Intramyocardial Coronary Artery Course—The Role of the Cardiopulmonary Exercise Test
8. Effects of β2-receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective β-blockers: a randomized trial
9. Heart failure and anemia: Effects on prognostic variables
10. Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias
11. The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study
12. Activities of daily living in heart failure patients and healthy subjects:when the cardiopulmonary assessment goes beyond traditional exercise test protocols
13. Symptomatic post COVID patients have impaired alveolar capillary membrane function and high VE/VCO2.
14. 356 DAPAGLIFLOZIN USE IN HEART FAILURE WITH REDUCED EJECTION FRACTION PATIENTS: A SINGLE CENTRE COMPARISON BETWEEN REAL-LIFE AND DAPA-HF DATA
15. 166 IMPACT OF PERSONAL PROTECTIVE MASKS ON CARDIORESPIRATORY VARIABLES IN HEALTHY SUBJECTS AND PATIENTS WITH HEART FAILURE: AN INTERIM ANALYSIS
16. 88 INCIDENTAL DIAGNOSIS OF MASSIVE MOBILE LEFT VENTRICLE THROMBI FOLLOWING COVID-19 INFECTION IN A HEART FAILURE PATIENT
17. 141 DIFFERENT KINETICS OF NT-PROBNP AND S-ST2 HIGHLIGHT DIFFERENT THERAPEUTIC THERAPEUTIC PATHWAYS OF SACUBITRIL/VALSARTAN
18. Heart failure patients with improved ejection fraction: Insights from the MECKI score database.
19. ACE-Inhibition Benefit on Lung Function in Heart Failure is Modulated by ACE Insertion/Deletion Polymorphism
20. Pick Your Threshold
21. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: The CARNEBI trial
22. Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis
23. Mediterranean diet impact on cardiovascular diseases: a narrative review
24. Can β-blockers influence regular daily physical activity?
25. Why Levosimendan Improves the Clinical Condition of Patients With Advanced Heart Failure: A Holistic Approach
26. Hemodynamic Effects of Exercise Training in Heart Failure
27. Effects of β-blockers on ventilation efficiency in heart failure
28. ORIGINAL RESEARCH—ERECTILE DYSFUNCTION: Erectile Dysfunction in Heart Failure: Correlation with Severity, Exercise Performance, Comorbidities, and Heart Failure Treatment
29. Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation
30. Alveolar Membrane Conductance Decreases as BNP Increases During Exercise in Heart Failure. Rationale for BNP in the Evaluation of Dyspnea
31. Respiratory Effects of β-blocker Therapy in Heart Failure
32. “You can leave your mask on”: effects on cardiopulmonary parameters of different airway protective masks at rest and during maximal exercise
33. Effects of carvedilol on oxygen uptake and heart rate kinetics in patients with chronic heart failure at simulated altitude
34. Chronotropic Incompentence and Functional Capacity in Chronic Heart Failure: No Role of β-Blockers and β-Blocker Dose
35. Minute ventilation/carbon dioxide production in chronic heart failure
36. The MECKI score initiative: Development and state of the art
37. Cardiac patient care during a pandemic: how to reorganise a heart failure unit at the time of COVID-19
38. Relationship of resting hemoglobin concentration to peak oxygen uptake in heart failure patients
39. Lateral Decubitus Position Generates Discomfort and Worsens Lung Function in Chronic Heart Failure
40. Erectile Dysfunction in Heart Failure: Correlation with Severity, Exercise Performance, Comorbidities, and Heart Failure Treatment
41. Exercise capacity in patients with β-thalassaemia intermedia
42. Spironolactone improves lung diffusion in chronic heart failure
43. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study
44. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison
45. Carvedilol Reduces the Inappropriate Increase of Ventilation During Exercise in Heart Failure Patients*
46. Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure
47. When should cardiovascular prevention begin? The importance of antenatal, perinatal and primordial prevention
48. Prognostic role of beta-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database
49. When should cardiovascular prevention begin? The importance of antenatal, perinatal and primordial prevention.
50. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.